Relatively-subdued COVID-19 fears
23/03/20 -"With aggravating COVID-19 fears and a material effect on the pharma supply chain – especially with respect to APIs, other than already known biosimilar risks, near-term earnings pressure is ..."
Pages
66
Language
English
Published on
23/03/20
You may also be interested by these reports :
05/11/25
The Q3 results missed expectations, as Novo contended with competition from compounding pharmacies and Eli Lilly. Moreover, the management again ...
04/11/25
The Q3 operating profitability exceeded expectations, though sales fell short of consensus. The management reaffirmed its full-year guidance. While ...
03/11/25
BioNTech reported mixed Q3 results. Sales significantly exceeded market expectations, but the operating loss was higher than anticipated. The 2025 ...
31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...